Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback